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ABSTRACT 
After injury, the adult mammalian central nervous system lacks long-distance axon 
regeneration, and insufficient repair results in the formation of a multicellular and 
compartmentalized scar. A great body of work has been dedicated to the study of the glial 
component of the scar, while the fibrotic lesion core has received less attention. This thesis 
aims to deepen our knowledge on the cellular origin and function of fibrotic scar tissue 
following central nervous system injury and disease. 
 
In Paper I we revealed that a subset of perivascular cells lining the vasculature, termed type 
A pericytes, is the major source of stromal fibroblasts that constitute the extracellular matrix-
rich fibrotic component of the central nervous system scar following spinal cord injury in the 
mouse. Maximal genetic inhibition of proliferation by type A pericytes largely abolished 
fibrotic scar tissue generation and resulted in unsealed lesions and impaired wound healing, 
highlighting the importance of pericyte-derived scarring in regaining tissue integrity and 
wound closure. On the other hand, moderate inhibition of type A pericyte proliferation 
preserved wound closure and resulted in attenuated fibrotic scar tissue generation. This 
represented an attractive scenario to investigate the role of pericyte-derived scarring in axonal 
regeneration and functional recovery after spinal cord injury. 
 
In Paper II we demonstrated that attenuation of pericyte-derived scarring is accompanied by 
decreased fibrosis, extracellular matrix deposition, astrogliosis and inflammation, and 
promoted regeneration of raphespinal and corticospinal tract axons caudal to the lesion. 
Corticospinal tract axons found below the injury site established functional synapses with 
local spinal neurons. Recovery of sensorimotor function was improved in animals with 
reduced pericyte-derived scarring. These results established pericyte-derived scarring as a 
therapeutic target to improve recovery following central nervous system injury. 
 
In Paper III we asked whether generation of periycte-derived scar tissue is preserved across 
diverse central nervous system lesions. In addition to traumatic spinal cord injury, we found 
that type A pericyte progeny detached from the vascular wall and generated fibrotic scar 
tissue, or contributed to tumor stroma, after traumatic brain injury, inflammatory 
demyelinating disease and in a glioblastoma tumor model, respectively. Following cerebral 
ischemic stroke, type A pericytes increased in number but remained associated with the 
vasculature. We found that humans also develop fibrotic tissue enriched in stromal fibroblasts 
after central nervous system lesions, such as spinal cord injury and multiple sclerosis. 
In Paper IV we showed that lesions to the spinal cord white matter trigger greater pericyte-
derived fibrotic scarring compared to grey matter lesions. We demonstrated that myelin 
damage, myelin itself and myelin-associated proteins function as potent inducers of pericyte-
derived fibrotic scarring, a process that is temporally synchronized with and dependent on the 
infiltration of peripherally derived macrophages. Reduction of monocyte-derived macrophage 
infiltration into the injured central nervous system or deletion of MAG, OMgp and Nogo, 
well-known myelin-associated axon growth inhibitors, resulted in attenuated fibrotic scar 
tissue generation following spinal cord injury.  
The work presented in this thesis collectively supports a role for pericytes in fibrotic scar 
tissue formation and fibrosis following central nervous system injury. Interfering with 
pericyte-derived scarring may represent a promising therapeutic strategy to facilitate 
recovery following central nervous system injury and disease.  
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RESUMO 
Após lesão, o sistema nervoso central de mamíferos adultos carece de regeneração axonal 
de longa distância, e a reparação insuficiente da lesão resulta na formação de uma cicatriz 
multicelular e compartimentalizada. Grande parte do trabalho de investigação desenvolvido 
tem-se dedicado ao estudo do componente glial da cicatriz, enquanto que o núcleo fibrótico  
da lesão tem sido menos estudado. Esta tese visa aprofundar o nosso conhecimento sobre a 
origem e função do tecido cicatricial fibrótico após lesão e em doenças do sistema nervoso 
central. No artigo I, revelámos que um subtipo de células perivasculares, denominado 
pericitos tipo A, é a principal fonte de fibroblastos do estroma que constituem o 
componente fibrótico, rico em matriz extracelular, da cicatriz do sistema nervoso central 
após lesão da medula-espinal do ratinho. A inibição genética máxima da proliferação dos 
pericitos do tipo A reduziu amplamente a formação de tecido cicatricial fibrótico e resultou 
em lesões não seladas e em deficiente cicatrização, salientando a importância das cicatrizes 
derivadas de pericitos na recuperação da integridade do tecido espinal e no fecho da lesão. 
Por outro lado, a inibição moderada da proliferação de pericitos do tipo A preservou o 
encerramento da ferida e resultou na formação atenuada de tecido cicatricial fibrótico. Este 
achado representou um cenário atraente para a investigação do papel das cicatrizes 
derivadas de pericitos na regeneração axonal e na recuperação de função após lesões da 
medula-espinal. No artigo II, demonstrámos que a atenuação de cicatrizes derivadas de 
pericitos é acompanhada por diminuição de fibrose, menor deposição de matriz extracelular 
e redução de astrogliose e inflamação, o que promoveu a regeneração dos axónios dos 
tractos rubro- e cortico-espinal abaixo do local da lesão. Os axónios do tracto cortico-
espinal encontrados abaixo do local da lesão, estabeleceram sinapses funcionais com os 
neurónios espinais locais. A recuperação da função sensório-motora foi também melhorada 
em animais com cicatrizes menos densas em pericitos. Estes resultados estabeleceram que a 
cicatrização fibrótica derivada de pericitos é um alvo terapêutico para melhorar a 
recuperação após lesão do sistema nervoso central. No artigo III, investigámos se a 
formação de tecido cicatricial derivado de pericitos se encontra preservada em diversas 
lesões do sistema nervoso central. Além da lesão traumática da medula espinal, 
descobrimos que as células derivadas dos pericitos tipo A se dissociaram da parede vascular 
e geraram tecido cicatricial fibrótico, ou contribuiram para o estroma tumoral, após lesão 
cerebral traumática, doença desmielinizante inflamatória e num modelo de glioblastoma, 
respectivamente. Após acidente vascular cerebral isquémico, os pericitos do tipo A 
aumentaram em número, mas permaneceram associados à vasculatura. Comprovámos ainda 
que os seres humanos também desenvolvem tecido fibrótico enriquecido em fibroblastos 
após lesões do sistema nervoso central, nomeadamente lesão da medula-espinal e esclerose 
múltipla. No artigo IV, demonstrámos que lesões na matéria branca da espinal-medula 
geram maior cicatrização fibrótica derivada de pericitos em comparação com lesões na 
matéria cinzenta. Demonstrámos que danos causados à mielina, a própria mielina e as 
proteínas a esta associada funcionam como indutores potentes da cicatrização fibrótica 
derivada de pericitos, um processo que é sincronizado temporalmente e que depende da 
infiltração de macrófagos de origem periférica. A redução da infiltração de macrófagos 
derivados de monócitos no sistema nervoso central danificado ou a exclusão de MAG, 
OMgp e Nogo, conhecidos inibidores do crescimento de axónios associados à mielina, 
resultaram na formação atenuada de tecido cicatricial fibrótico após lesão medular. 
O trabalho apresentado nesta tese suporta colectivamente um papel dos pericitos na 
formação de tecido cicatricial fibrótico e fibrose após lesão no sistema nervoso central. A 
manipulação das cicatrizes derivadas de pericitos pode, assim, representar uma estratégia 
terapêutica promissora para facilitar a recuperação após lesão ou em casos de doenças que 
afetam o sistema nervoso central. 
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1 INTRODUCTION 
 
A healing response, involved in restricting tissue damage and restoring homeostasis, takes 
place after injury, and is followed by an attempt to restore tissue and organ function. 
Inflammation is coupled to active rebuilding and remodeling of the ECM, extensive cell 
proliferation and migration associated with dynamic restructuring of the tissue architecture, 
are conserved repair processes, although their success in restoring function varies across 
different tissues and species.  
A scar, consisting of a multitude of resident and non-resident interacting cell types embedded 
in a complex ECM, forms as the result of attempted wound repair in mammalian organs. In 
various peripheral organs, the scar goes through a resolution phase and there is restoration of 
basic tissue functions, although not necessarily recapitulating the pre-injury state. Organs 
showing high regenerative capacity, such as the skin and the gastrointestinal tract, recruit 
resident stem cells to sustain tissue function. Whereas, organs presenting lower cellular 
turnover, such as the liver and lungs, mainly depend on proliferation of committed progenitor 
pools (1). 
In the CNS, tissue scarring exhibits a higher degree of complexity. It is commonly 
accompanied by reactive tissue changes such as inflammation, altered deposition of ECM 
components, fibrotic scarring and reactive gliosis (2–4). Injury-induced remodeling programs 
fail to reestablish tissue organization and pathology remains chronically, compromising tissue 
functions within and surrounding the non-resolving scar tissue (2). It has been increasingly 
recognized over the years that scar tissue, as a healing response, is highly necessary to 
contain the damage and limit further injury spread. However, the cellular and extracellular 
components of the scar microenvironment do also play key roles in limiting functional repair 
and contribute to the failure of axon regeneration after CNS injury (3, 5). 
Among several other CNS pathologies that exhibit reactive tissue changes and scarring, 
wound repair is particularly inefficient and pathological changes persist chronically after 
traumatic SCI. Increased levels of infiltrating leukocytes with a capacity to exacerbate tissue 
damage and enhanced expression of inflammatory cytokines, associated with remarkable 
astrocyte activation and ECM deposition, may underlie the limited capacity for repair of the 
injured spinal cord compared to brain injuries (2–4, 6–9). 
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2 TISSUE SCARRING IN THE INJURED CNS 
 
2.1 CASCADE OF CELLULAR EVENTS FOLLOWING TRAUMATIC AND 
ISCHEMIC INSULTS 
 
Acute focal injuries in the CNS, including traumatic injury and ischemic stroke, trigger 
wound repair with tissue replacement. A complex multicellular response is elicited, in which 
CNS intrinsic neural-lineage cells (neurons, oligodendrocytes, OPCs, astrocytes and 
ependymal cells) interact with non-neural resident cells, including microglia, endothelial 
cells, meningeal fibroblasts, pericytes and other perivascular cells (3, 5). Peripheral 
myelinating Schwann cells can also migrate and invade the CNS after injury (10). 
Additionally, monocyte-derived macrophages, neutrophils and lymphocytes (T cells, B cells 
and NK cells) as well as other bone marrow-derived cells such as fibrocytes and platelets are 
recruited from the circulation and infiltrate the injured CNS (5). Acute focal traumas caused 
by contusion or crush are accompanied by pronounced vascular damage and therefore, 
present many similarities to ischemic injury, such as cerebral ischemic stroke.  
CNS responses to acute focal injury trigger a multitude of sequential and overlapping events 
that can be split into three main phases (5), summarized in Figure 1. 
 
 
Figure 1 | Phases and time course of multicellular responses following acute focal CNS insults…………….. 
Traumatic and ischemic injuries to the CNS trigger a complex cascade of overlapping but distinct events, that 
include cell death and inflammation (Phase I), cell proliferation and replacement (Phase II), and tissue 
remodeling (Phase III), and involve the crosstalk among neural and non-neural cells intrinsic to CNS and non-
neural cells infiltrating from the circulation……………………………………………………………………….. 
Reprinted (5), © 2014, with permission from Elsevier.   
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2.1.1 Phase I - Cell death and inflammation 
Seconds to hours after the primary insult and subsequent events that gradually 
develop over days 
 
A traumatic or ischemic insult leads to acute death of local cells and axonal damage, 
disruption of the vasculature and loss of integrity of the BBB/BSB. Endothelial cell trauma 
rapidly triggers platelet adhesion and activation, the coagulation cascade and blood clot 
formation at the injury core (5, 11, 12). The initial damage initiates a secondary injury 
cascade characterized by haemorrhage, local oedema and swelling, release of cytotoxic 
products and cell death, in particular neurons and oligodendrocytes (11). Microglia promptly 
sense and migrate towards the site of tissue damage to protect against spread of damage, 
initiate the clearance and removal of debris and stimulate the recruitment of other cells (13–
15). Neutrophils, lymphocytes and peripherally-derived macrophages infiltrate the injured 
CNS to scout for pathogens, phagocytose debris and instruct the wound repair process (16, 
17). In contrast to OPCs that show chemotaxis towards the injury zone (18, 19), astrocytes do 
not migrate but become reactive and hypertrophic, and occasionally proliferate. Following 
severe trauma or ischemia, astrocytes in the lesion center can die (20–23). Tissue reperfusion 
potentiates oxidative stress and glutamate excitotoxicity-mediated death of neighboring 
neurons and glia, and further axonal damage (24). The sustained secondary injury cascade 
exacerbates and often surpasses the damage caused by the initial insult.    
 
2.1.2 Phase II - Cell proliferation for tissue replacement  
2 to 10 days after the primary insult 
 
The proliferative and tissue replacement phase that takes place in response to acute CNS 
tissue damage resembles in many aspects classic wound healing responses in other tissues 
(25–27). It is characterized by prominent proliferation of endothelial cells and progenitors, 
involved in neovascularization of the injury site via sprouting angiogenesis (28, 29). 
Additionally, widespread deposition of ECM molecules, proliferation and migration of 
inflammatory cells, fibroblast-lineage cells and pericyte-derived cells (Paper I) contribute to 
tissue replacement by forming fibrotic scar tissue (30–33). Although angiogenesis takes 
place, the integrity of the BBB/BSB in the lesion core is not reestablished yet and the leaky 
vessels allow free extravasation of serum proteins and other molecules into the neighboring 
neural parenchyma (34). Additionally, there is extensive proliferation of CNS intrinsic neural 
cells, including local astrocytes, scar-participating OPCs and ependyma-derived cells that 
later assemble and participate in the formation of a mature CNS scar (19, 35–45). 
Interestingly, striatal parenchymal astrocytes are able to enter a neurogenic program and 
generate neuroblasts that later mature into neurons after cerebral ischemic stroke, a process 
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that depends on Notch signaling (18, 46, 47). Likewise, forebrain ependymal cells were 
shown to produce neuroblasts and astrocytes in response to ischemic stroke, via a Notch 
dependent mechanism (48). Moreover, in response to acute CNS damage in the forebrain, 
subventricular zone-lining neural stem cells generate progeny that migrate towards the 
injured cortex and striatum and contribute to newly generated neurons and glial cells in 
perilesion perimeters (49–52).  
 
2.1.3 Phase III - Tissue remodeling  
From the end of the first week after the primary insult 
 
The tissue remodeling phase is marked by the organization of injury-participating cells as 
well as extracellular components that assemble to form the CNS scar, and by the restoration 
of the BBB/BSB and neurovascular unit around newly formed blood vessels of the lesion 
penumbra (33, 34, 53).   ……………………………………………………………………….  
Reactive astrocytes become hypertrophic, upregulate the expression of intermediate filaments 
such as nestin, vimentin and GFAP and extend well-organized interdigitating processes (21, 
54–57) that form a barrier-like structure (58) and flank a fibrotic lesion core of non-neural 
tissue by 2 to 3 weeks after an acute CNS insult (45). As axons continue to degenerate and 
retract away from the lesion center, oligodendrocyte death continues, triggering additional 
local tissue responses. With time, remodeling of the lesioned tissue continues with gradual 
contraction of glial and fibrotic scar components, and ongoing alterations in the composition 
of the ECM (32, 59–61). As acute inflammatory responses taper off, the spared but reactive 
neural tissue surrounding mature lesions undergoes a gradual and continuous remodeling of 
neural circuits and attempt to remyelinate denuded axons (2, 12).                      ……...………. 
In humans and rats, thin bands of fibrous tissue and macrophages develop around cysts after 
some types of traumatic SCI and further restrict axonal regrowth and cell migration. (3, 62–
67). 
 
2.2 SCAR FORMATION AFTER TRAUMATIC SCI 
 
The lesion environment is a complex mixture of interacting cell types that react to injury in a 
stereotyped fashion, forming a mature scar (2, 3, 5, 68). Over the last decades, astrocytes, 
NG2-expressing OPCs, ependymal cells, peripherally-derived macrophages, microglia, 
meningeal cells, pericytes and other perivascular cells have been investigated in the context 
of scar formation after CNS trauma, namely SCI (2, 3, 5, 68). ………………………………..  
The mature CNS scar that forms after traumatic SCI, erroneously referred to as the glial scar 
as a whole, can be grossly viewed as a two-compartment structure, where a reactive glial scar 
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border intimately flanks a central lesion core filled with non-neural fibrotic tissue, often 
referred to as fibrotic scar (Figure 2). Additionally, a large perilesion area of functional but 
reactive neural tissue exhibiting attenuating reactive gliosis that gradually transitions to 
healthy tissue can be appreciated and was recently proposed as a third compartment of the 
chronic matured scar (3, 5). Despite becoming spatially segregated in a chronic scar, there is 
temporal dependence and bidirectional cross talk amongst scar components.  
 
2.2.1 Glial scar  
 
Severe tissue damage accompanied by BBB/BSB breakdown, extravasation of serum 
proteins into the CNS parenchyma and leukocyte infiltration, trigger rapid migration of 
astrocytes away from the inflammatory epicenter (2). These processes initiate the formation 
of a glial, or astrocyte, scar at the lesion penumbra, characterized by astrocyte hypertrophy. 
Hypertrophic astrocytes undergo massive restructuring that leads to the formation of compact 
astrocyte scars, a specialized aspect of reactive astrogliosis, which depends on IL-6 receptor-
STAT3 and LKZ signaling (35, 45, 57).  
Glial scar formation around central lesion cores is largely completed by 2–4 weeks after 
traumatic SCI, a time when the lesion is considered mature and enters its chronic stage. The 
compact glial scar border serves to directly demarcate and contain areas of fibrotic non-
functional lesion core tissue from the immediately surrounding viable but reactive neural 
tissue. It is composed of densely packed astrocytes with elongated processes that intermingle 
and intertwine extensively and some NG2-expressing OPCs. Spinal cord astrocytes and 
central canal linining-ependymal cells are the two main cellular sources of newly proliferated 
scar-forming astrocytes after SCI in rodents (38, 42, 45, 69). In response to trauma, NG2-
expressing OPCs proliferate and migrate towards the injury site. Apart from their known role 
in generating remyelinating oligodendrocytes, either by oligodendrogenesis or via 
differentiation into remyelinating Schwann cells (10, 70–73), NG2-expressing scar-
participating OPCs hyperthrophy, upregulate NG2, accumulate within the glial scar and some 
differentiate into astrocytes, after traumatic SCI (18, 36–38, 74, 75). 
In contrast to peripherally-derived macrophages that associate with fibroblast-lineage cells in 
the lesion core, microglia proliferate and accumulate at the interface between fibrotic and 
astroglial scars after SCI (14, 76–78).  
 
2.2.2 Fibrotic scar  
 
The wound healing response triggered by CNS injury recruits local and infiltrating immune 
cells, as well as ECM-producing stromal fibroblasts. Although some tissue remodeling is 
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appreciated over time, these cells do not withdraw entirely and are not replaced by 
regenerated tissue, persisting chronically in the lesion core (79).  
The mature CNS scar presents a central lesion core, often referred to as the fibrotic scar 
(alternative nomenclature includes: mesenchymal, fibrous, collagenous matrix or connective 
tissue scar), composed of non-neural tissue, and immediately surrounded by the glial 
component of the scar (3, 79). Major components of this non-neural tissue are endothelial 
cells and progenitors, inflammatory immune cells, including monocyte-derived macrophages, 
stromal fibroblasts, also referred to as fibroblast-related cells or fibroblast-like cells, and 
ECM deposits (3, 80). Endothelial cells, stromal fibroblasts and monocyte-derived 
macrophages contribute to the excessive deposition of connective tissue matrix. In addition to 
numerous others ECM components, the lesion core contains glycoproteins such as CSPG and 
HSPG, and collagens, fibronectin and laminin (32, 60, 61, 81–84). The prolonged presence of 
these matrix molecules delays tissue remodeling by fueling fibrosis and scarring via 
interaction with inflammatory cells (2, 85). 
The origin of stromal fibroblasts residing in fibrotic scar tissue after CNS injury and disease 
was investigated in Papers I and III. 
 
2.2.3 Interaction of cellular scar components  
 
Due to their strategic location at the glial-fibrotic interface of the scar, reactive astrocytes can 
interact and be influenced by stromal fibroblasts and inflammatory cells (45). After CNS 
injury, reactive CNS astrocytes expressing the ephrin-B2 ligand intermingle with stromal 
fibroblasts expressing the EphB2 receptor. This interaction culminates with the formation of 
restricted cellular domains containing dense networks of cells and interweaving processes and 
the establishment of an astroglial-fibrotic lesion border in the sub-acute phase after SCI (86). 
More recently, type-I collagen, expressed by stromal fibroblasts within the lesion core,  was 
found to induce astrocytic scar formation via the integrin–N-cadherin pathway (87). In 
another recent study, perivascular PDGFRβ-expressing cells (described as reactive pericytes) 
were found to upregulate the expression of the ECM molecule periostin after SCI and 
mediate the upregulation of TNFα  from infiltrating monocyte/macrophages to promote scar 
formation, type-I collagen deposition and fibrosis after SCI (88).  
Perivascular astrocyte endfeet lie in a prime location and intimately border the basal lamina 
of endothelial cells at the BBB/BSB, making astrocytes pivotal regulators of resident and 
infiltrating immune cells during CNS scar formation (89). Indeed, the release of CCL2, IL-
1β, IL-6 and other chemokines and cytokines by reactive astrocytes triggers polarization of 
microglia and peripherally-derived macrophages into a pro-inflammatory phenotype. The 
release of inflammatory mediators such as IFN-γ, IL-6, IL-1β and TNFα by immune cells 
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triggers astrocyte reactivity and astrogliosis (21). Interestingly, activated neuroinflammatory 
microglia are capable of inducing a neurotoxic phenotype in reactive astrocytes, via the 
release of Il-1α, TNF and C1q (21, 90). Additionally, microglia/macrophages express the 
ECM-associated protein osteopontin and promote glial scar formation after ischemic brain 
injury via binding to αvβ3 integrin on reactive astrocytes (91). 
Apart from direct cellular interactions, parenchymal cells can sense signals from the injury 
milieu and indirectly influence the behavior of neighboring cells (2). 
 
Figure 2 | Scar formation after traumatic SCI                                       
Schematic representation of the uninjured, and 
injured spinal cord at subacute and chronic 
stages after a contusive type lesion in the rat.  
SCI triggers a complex multicellular response, 
involving CNS resident and non-resident cell 
types, which culminates with the formation of a 
scar at subacute stages, that persists chronically. 
In the subacute stage, there is substantial loss of 
neurons, axons, oligodendrocytes and myelin. 
Axons retract away from the lesion epicenter. 
Activated microglia, infiltrating monocyte-
derived macrophages, among other 
inflammatory immune cells, are recruited to the 
injury site and assist in the clearance of myelin 
debris. The CNS scar exhibits a central fibrotic 
component, packed with inflammatory cells and 
stromal fibroblasts, surrounded by an outer glial 
component, made of reactive astrocytes and 
some NG2-expressing OPCs.....………………...  
In the chronic phase, OPCs and Schwann cells 
contribute to generation of newly myelinating 
oligodendrocytes. Scar maturation is 
accompanied by a dampened, but persisting, 
inflammatory response, and cavitation, in the rat 
after contusion SCI. Fibrotic and glial scar 
components remain chronically..Reprinted by        
……………..permission from Springer Nature (92), © 2017. 
 
2.2.4 Dual role of scar components  
 
Increasing evidence supports a dual, and seemingly opposing, role of the CNS scar, in both 
promoting tissue protection but also inhibiting repair..……………………………………….  
Scar-forming astrocytes have been extensively studied and regarded as one of the main 
sources of axon growth inhibitory CSPGs (93–99). However, the notion that astrocyte scars 
 8 
act as a physical and molecular barrier that hinders rather than aids axon regeneration was 
recently challenged (87, 100). A potential source of discrepancy may arise from the 
heterogeneous origin of scar forming-astrocytes (38, 42). Selectively blocking the generation 
of ependymal cell-derived scar-forming astrocytes after SCI revealed their importance in 
restricting secondary tissue damage and mediating tissue protection and, therefore, supporting 
regeneration (40, 41). This is in agreement with other studies that recognize the vital role of 
reactive astrocytes in bordering the fibrotic lesion core and shielding nearby viable neural 
tissue from destructive inflammation (34, 35, 43, 45, 55, 57, 100–104). It has also been 
documented that adult mammalian CNS astrocytes form permissive bridges in vivo, known as 
glial bridges, along which injured CNS axons can regrow and cross the scar when stimulated 
with appropriate growth factors, grafts, and by genetic activation of neuronal intrinsic growth 
programs (100, 105–108). 
Activated macrophages and microglia dominate sites of CNS injury and play crucial roles in 
promoting tissue remodeling and repair by clearance of cellular and myelin debris, 
degradation of scar tissue and production of growth factors, but can also drive secondary 
injury through a vicious neurotoxic inflammatory cycle (109). Depending on the 
microenvironment and route of entry into the injured CNS, macrophages can polarize into a 
classically activated pro-inflammatory and detrimental phenotype (named M1) that can cause 
neurotoxicity, or an alternative, anti-inflammatory pro-repair phenotype (named M2) (78, 
110, 111). Given the pro-inflammatory milieu within the injured spinal cord, there is a 
predominance of an M1 macrophage response that perpetuates and is only counteracted by a 
smaller and temporary M2 macrophage response. Although of common origin, monocyte-
derived M1 macrophages infiltrate the CNS via the adjoining spinal leptomeninges, while 
monocyte-derived M2 macrophages enter from the brain-ventricular choroid plexus of the 
blood-cerebrospinal fluid barrier (111). A similar pattern of polarization is observed in 
microglia following injury (112). M1 pro-inflammatory, neurotoxic microglia posses low 
phagocytic activity and are involved in secondary tissue damage and glial scar formation after 
SCI (113, 114). In turn, M2 microglia possess increased phagocytic activity, produce growth 
factors and anti-inflammatory cytokines and thereby, stimulate tissue repair and regeneration 
(112).  
Activated microglia were recently shown to promote tissue repair and constitute an essential 
component of the neuroprotective scar that forms after SCI. The elimination of microglia in 
the subacute phase after traumatic SCI leads to reduced astrocyte proliferation and disruption 
of the glial scar, and increased infiltration of monocyte-derived macrophages, resulting in 
increased death of oligodendrocytes and neurons, and impairing functional recovery (14, 77) . 
In addition to its well-known activity in limiting axonal growth and representing a major 
obstacle for CNS recovery after injury, CSPG deposition was shown to play a key role in 
controlling the secretion of neurotrophic factors by resident microglia and infiltrating 
monocyte-derived macrophages, thereby promoting repair and functional motor recovery 
during the acute phase after traumatic SCI, but not at later stages (115, 116).  
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Following CNS injury, NG2-expressing OPCs were shown to migrate towards the lesion site 
and participate in the formation of the glial scar, a structure that, as discussed above, exerts 
neuroprotective effects by limiting the spread of neurotoxic inflammatory lesion core cells. 
Interestingly, NG2 glia was also found to entrap dystrophic axons by forming synaptic-like 
connections (117) and stabilize dystrophic axons undergoing pro-inflammatory macrophage-
mediated axonal dieback after SCI (118–120).  
In Papers I and II, we will present evidence for a dual role of pericyte-derived scar tissue 
after SCI. On the one hand, scar-forming pericyte-derived cells are essential for sealing off 
the lesion site and the reestablishment of tissue integrity. On the other hand, pericyte-derived 
fibrotic scarring inhibits axon regeneration and limits functional recovery following SCI (30, 
79). 
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3 STROMAL FIBROBLASTS - CELL OF ORIGIN 
 
Scar formation has been reported in humans and experimental animal models in response to 
traumatic lesions to the brain and spinal cord, stroke, autoimmune demyelinating lesions, 
such as MS, and tumors (5, 6, 102, 121–131).  
The glial component of the CNS scar that forms in adult mammals has been extensively 
studied and is mainly composed of reactive astrocytes (36, 38, 94). Although acknowledged, 
the fibrotic component of the scar, mostly comprised of inflammatory immune cells and 
stromal fibroblasts, has received less attention. In particular, the cellular origin of stromal 
fibroblasts that form fibrotic scar tissue has been difficult to establish.  
Fibroblasts are versatile tissue-resident mesenchymal cells found in the interstitial space of 
organs. These cells are typically spindle-shaped and present an oval flat nucleus. Fibroblasts 
can produce or respond to a wide range of cytokines and their primary function is to 
synthetize, secrete ECM proteins, including collagens, tenascin, laminin, fibronectin and 
proteoglycans (132). Together with endothelial cells and macrophages, activated fibroblasts 
are critically involved in the remodeling phase of wound healing. Under conditions in which 
successful wound healing occurs, fibroblasts differentiate into αSMA-expressing 
myofibroblasts that can produce and secrete ECM and actively participate in the wound 
closure process by promoting tissue contraction (132). As tissue remodeling progresses and 
adequate ECM has been deposited, fibroblasts and myofibroblasts gradually disappear, 
thereby limiting disproportionate ECM secretion and dampening the pro-inflammatory and 
pro-fibrotic environment (132).  
Due to the ongoing persistent inflammation (133, 134), these cells are not cleared off from 
CNS scar tissue and, together with inflammatory cells, cluster at the lesion core and remain 
indefinitely.  
In the CNS, several cell types have been proposed to contribute to scar-forming stromal 
fibroblasts and are discussed below.  
 
3.1 SPINAL CORD INJURY 
 
Following traumatic injuries to the mouse spinal cord, including dorsal hemisection, 
contusion and crush spinal lesions, fibrotic scar tissue accumulates at the lesion core 
surrounded by a glial scar (Figure 3A,E) (30, 31, 106, 107, 135, 136). Rats and humans, but 
not mice, show cavitation at the lesion site after contusive spinal injuries (62, 66, 137). 
Interestingly, fibrotic scarring still occurs in these contusion injuries containing multiple 
hemorrhagic and necrotic regions (3, 31, 62, 76, 135, 137–139). Additionally, generation of 
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fibrous scar tissue enriched with inflammatory cells and excessive ECM deposits is observed 
after crush, compression and lacerating spinal injuries in humans (3, 62, 137, 139, 140). 
Spinal crush in rodents is, therefore, a clinically relevant model of human SCI that occurs as a 
result of vertebral crush or displacement (106, 107, 136, 141). In cases the dura mater is 
breached, meningeal fibroblasts can infiltrate the lesion site and contribute to fibrotic tissue 
generation (86, 142–144).  
Collectively, different scar-participating cell types, including stromal fibroblasts, meningeal 
fibroblasts, monocyte-derived macrophages, astrocytes, and endothelial cells, contribute to 
the deposition of excessive amounts of fibrillar collagens (types I, III, and V), fibronectin, 
tenascin-C, periostin, in addition to basal lamina components, such as laminins and collagen 
type IV, and mediate tissue fibrosis in SCI (3, 59, 88, 135, 138, 143, 145–149).  ……………. 
Until our work (Papers I and III), CNS-resident perivascular fibroblasts (31, 76) or 
meningeal-derived fibroblasts have been suggested as the primary source of scar-forming 
stromal fibroblasts after SCI (32, 84, 144, 150–152). 
 
3.2 TRAUMATIC BRAIN INJURY 
 
Brain trauma is accompanied by disruption of the BBB, acute pericyte loss and accumulation 
of inflammatory cells into the lesion area, followed by scar formation (143, 153). A fibrotic 
lesion core enriched in PDGFRβ-expressing stromal fibroblasts and fenced off by a glial scar 
develops after penetrating and non-penetrating injuries to the brain, such as stab wounds 
(Figure 3B,F) and cortical controlled impact and lateral fluid percussion-induced injuries, 
respectively (143, 153)...……………………………………………………………………… 
Pericytes were shown to detach from the vascular wall within the first hour after TBI (154). 
Pericyte-derived cells and fibroblasts invading from the nearby meninges have been 
suggested to deposit ECM, including collagen type IV, fibronectin and laminin, and generate 
fibrotic tissue after brain injury (81, 143, 153, 155–160). 
 
3.3 STROKE 
 
After cerebral ischemic stroke, a glial scar develops and surrounds an ischemic lesion core 
undergoing extensive vascular remodeling in both humans and rodents (161–163) (Figure 
3C,G). Increased expression of PDGFRβ, fibronectin, collagen type 1 and periostin was 
reported within the ischemic stroke core and in perilesion areas (164–171). …………………. 
A dense network of PDGFRβ-expressing cells, presumably derived from the neurovascular 
unit, was suggested to deposit fibrous ECM and contribute to post-ischemic scarring (121, 
131, 171). In addition, a meningeal-derived population of Col1a1-expressing perivascular 
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stromal cells was suggested to generate fibrotic scar tissue after experimental cerebral 
ischemia (172). Bone marrow-derived cells do not appear to participate in fibrotic scarring in 
the post-ischemic brain (121, 131).  
 
3.4 MULTIPLES SCLEROSIS  
 
MS is an autoimmune demyelinating disease of the CNS characterized by the presence of 
multiple white matter scars across the brain and spinal cord. Demyelination with axonal 
damage, glial scar formation and perivascular aggregates of PDGFRβ–expressing cells 
intermixed with monocyte-derived macrophages and lymphocytes, are detected near post-
capillary venules following EAE in the mouse (Figure 3D,H) and in active MS brain lesions 
(128–130).  
Extensive deposition of fiber-like ECM within inflammatory perivascular cuffs, including 
accumulation of fibrillar collagens, fibronectin, agrin, biglycan and decorin, is apparent in 
both active MS lesions and following EAE (126, 128, 130, 173–175). In addition, 
perivascular and parenchymal expression of tenascin-C and -R proteins, laminins, CSPGs, 
HSPGs, and DSPGs is altered within demyelinated areas. 
 
3.5 BRAIN TUMORS 
 
Reactive gliosis and the presence of a tumor stroma enriched in ECM, vasculature, 
inflammatory immune cells and stromal fibroblasts are characteristics of brain tumors, such 
as glioma (124).  
 
 
 
Collectively, all the aforementioned studies acknowledge the presence of fibroblasts in 
fibrotic tissue following CNS injury and disease. However, no genetic lineage tracing 
strategies have been employed in these studies to unequivocally sort out the cellular origin of 
scar-forming stromal fibroblasts.  
The cellular origin of stromal fibroblasts that form fibrotic scar tissue following penetrating 
and non-penetrating SCI, TBI, MCAO-induced ischemic stroke, EAE and in a glioblastoma 
tumor model was subjected to investigation in Papers I and III. 
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Figure 3 | Scar formation following lesions to the adult mammalian brain and spinal cord 
Fibrotic scar (FS; PDGFRβ) and glial scar (GS; GFAP) components following complete crush SCI (A,E), 
cortico-striatal stab lesion (B,F), MCAO-induced ischemic injury (C,G) and EAE (D,H). ………………………  
A,E and B show sagittal views of the injured spinal cord and brain, respectively; C,F,G and D,H show coronal 
views of the brain and spinal cord, respectively. Scale bars represent 100 µm (B,E-H) and 200 µm (A,C,D). 
Reproduced from (79). 
 
3.6 MANIPULATION OF FIBROTIC SCAR TISSUE TO PROMOTE AXON 
REGENERATION 
 
When a CNS axon is transected, the distal segment undergoes Wallerian degeneration. 
However, the proximal portion of the axon initially retracts away from the original site of 
injury, a process known as axonal dieback, but its neuronal cell body can subsist for years 
after axotomy (176–178). Some severed axons initiate a growth response but ultimately fail 
to cross beyond the lesion (94, 179) site and form dystrophic end bulbs (180). The lack of 
adequate regeneration in the adult CNS following injury results in permanent functional 
deficits. Major factors hindering axon regeneration include a poor intrinsic capacity of 
severed axons to grow (106, 181), a long-lasting inflammatory response (182) and the lesion 
extracellular environment that contains molecules which restrict neurite outgrowth and 
plasticity such as CSPGs (179, 183) and myelin-associated proteins (i.e. Nogo , MAG and 
OMgp) (184–186), as well as scar formation. 
Scar formation characterized by a glial component surrounding a fibrotic component, does 
not occur in neonatal rodents less that 8 days old when injured, as no deposition of collagen 
and only transient gliosis are observed. The change to mature scarring occurs from around 
postnatal days 8–12 in rodents when deposition of collagen and formation of a glial scar 
around a fibrotic lesion core containing fibroblasts and macrophages can be identified in CNS 
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wounds (159, 187, 188)...…………………………………………… ………… …………….. 
The fibrotic lesion core of the adult CNS scar contains growth-promoting substrates for re-
growing axons, such as laminins, fibronectin and collagen IV (100, 138, 149, 189–193). 
Nonetheless, the excessive deposition of these basement membrane proteins is thought to 
create a binding matrix for a plethora of axon growth inhibitory molecules (32), including 
chondroitin, keratan and heparan sulfate proteoglycans, tenascin-C, EphB2 and semaphorin 
3A (86, 97, 144, 149–151, 194–197), that accumulate at the lesion site to high local 
concentrations. Therefore, the overall fibrotic scar milieu is thought to weakly support or 
inhibit regrowth of injured axons.……………………………………………………………...  
Pharmacological modification or removal of certain ECM components present at the lesion 
site has proven some success to improve axonal regeneration after SCI and brain lesions (32, 
146, 148, 198, 199). For example, anti-scarring treatment combining the iron chelator BPY-
DCA, which temporarily suppress collagen IV biosynthesis, and cAMP, which inhibits 
proliferation of meningeal fibroblasts, reduces collagen deposition at the lesion core and 
enhances axon regeneration after SCI and brain lesions (148, 199). Additionally, treatment 
with the iron chelator deferoxamine and inhibition of lysyl oxidase, a key enzyme in collagen 
biosynthesis, leads to improved axon regeneration and accelerates recovery after SCI (152, 
200). …………………………………………..……. 
Stabilization of microtubules with antimitotic agents such as taxol or Epothilone B prevents 
dystrophic growth cone formation and is accompanied by  reduced fibrotic scarring, enabling 
axonal regeneration and functional recovery (139, 201)...…………………………………….  
Stromal fibroblasts in the lesion core of CNS lesions express the chemorepellent molecule 
semaphorin 3A that inhibits outgrowth of injured neurites (144, 150, 151, 202). Inhibition of 
semaphorin 3A leads to robust axon regeneration after spinal lesions (203). Stromal 
fibroblasts also upregulate the expression of EphB2 receptor after SCI (86). Conditional 
deletion of the inhibitory axonal guidance molecule and corresponding ligand ephrin B2 in 
scar-forming astrocytes decreases gliosis, and improves axonal regeneration and motor 
recovery after SCI (204). Additionally, TGF‐β1 drives fibrotic scarring by binding to type I 
and type II TGF‐β receptors that are strongly induced in stromal fibroblasts after CNS injury 
(156). Application of TGF‐β1 inhibitors or neutralizing antibodies was also shown to reduce 
the generation of fibrotic scar tissue after cerebral wounds and promote axon regeneration 
(205–207). 
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4 STROMAL FIBROBLASTS - PERICYTES AS A 
CANDIDATE CELL OF ORIGIN  
 
Fibrotic tissue generation, where excessive ECM proteins are deposited by a large number of 
fibroblasts, is a major feature of scarring and fibrosis across all organs and in diverse types of 
pathology (27). Although recognized for a long time, the source of CNS scar-forming stromal 
fibroblasts has been difficult to establish (79). 
Recent studies have implicated pericytes and perivascular fibroblasts as the major source of 
ECM-producing (myo)fibroblasts found in conditions such as kidney, lung and liver fibrosis, 
and dermal and muscle scarring (208–213). 
 
4.1 CNS PERICYTES 
 
Although Eberth described the existence of pericytes in 1871 (214), the discovery of a 
population of contractile cells surrounding the endothelial cells of blood vessels is usually 
attributed to the French scientist Charles-Marie Rouget (215). The term ‘pericyte’ was later 
coined by Zimmermann in 1923, referring to their proximity to endothelial cells. Based on 
morphology, location and function, he proposed the existence of multiple subsets of pericytes 
(216–218) 
CNS pericytes are vascular mural cells surrounding blood microvessels of the CNS. They are 
embedded within the vascular basement membrane and send cytoplasmic processes along the 
abluminal surface of the endothelial tube of capillaries, pre-capillary arterioles and post-
capillary venules (219). Another kind of mural cells, termed vascular SMC, enwraps large 
diameter vessels, such as arteries and veins. Collectively, pericytes and microvascular SMC 
are called microvascular mural cells, or MMCs. Other non-mural periendothelial, or 
perivascular, cells include fibroblasts, adventitial cells and macrophages. Under homeostatic 
conditions, pericytes are seemingly present along all blood microvessels, but normally 
asbsent in lymphatic capillaries.  Coverage of the vasculature by pericytes is the highest in the 
CNS, with about 30% of the endothelial tube surface being covered by pericytes (220, 221).  
Pericytes establish a ‘peg and socket’ type contact with endothelial cells at discrete points of 
discontinuous vascular basement membrane. Adhesion plaques and occluding type contacts 
have also been described. Additionally, gap junction-like structures have been reported 
between pericytes and endothelial cells (222, 223).   
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4.1.1 Multifunctional role 
 
The NVU is comprised of a group of vascular cells (mural cells and endothelial cells), glial 
cells (astrocytes, oligodendrocytes and microglia) and neurons that work in consonance to 
regulate cerebral blood flow and maintain the integrity of the BBB/BSB (33, 224, 225). Due 
to their strategic location in the NVU, between endothelial cells, astrocytes and neurons, 
pericytes serve as a hub, receiving signals from their surrounding cells, and convey functional 
responses that are indispensable for proper CNS functioning (Figure 4A,B).  
 
 
Figure 4 | The multifunctional role of CNS pericytes                                                                                             .  
(A) Simplified diagram of the NVU at the level of brain capillaries, highlighting the communication between 
endothelial cells, pericytes, astrocytes and neurons.                                                                                                    .  
(B) Roles of pericytes under physiological conditions (top row) and consequences of pericyte dysfunction at the 
NVU (bottom row)………………………………………………………………………………………………… 
Reprinted by permission from Springer Nature (219), © 2016.  
 
CNS pericytes play a vital role in the maturation, maintenance and permeability of BBB/BSB 
(226–228). This diffusion barrier is composed by an uninterrupted monolayer of endothelial 
cells that establishes continuous crosstalk with mural cells and astrocytes within the NVU 
(219, 229). It limits paracellular and transcellular endothelial transport of various 
macromolecules and toxins from the blood to the brain. Pericytes control BBB permeability, 
in part by regulating bulk-flow transcytosis of fluid-filled vesicles across the BBB (226–228, 
230). Additionally, pericytes are implicated in the regulation of angiogenesis and stabilization 
of the microvasculature during CNS development and vascular remodeling (33, 222, 231). 
Whether pericytes are involved in the regulation of capillary blood flow is still under debate 
(232–235).  
Among other functions, pericytes are involved in the clearance of amyloid-β peptide, as 
shown in a murine Alzheimer's disease model (236) and can display phagocytic activity in 
vivo (228, 236, 237). Under cytokine-mediated inflammation, neutrophils traffic through the 
venular walls at specific exit points, coinciding with areas of low pericyte coverage and 
discontinuous basement membrane (238, 239). …………….…………………………………  
A number of studies have associated pericyte degeneration with breakdown of the BBB/BSB 
and accumulation of blood-derived neurotoxic molecules into the CNS parenchyma (228, 
230, 240–242). Interestingly, pericytes were recently shown to support neuronal survival 
through production of the neurotrophic growth factor pleiotrophin (242). Following cerebral 
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ischemia, pericyte rigor mortis leads to constriction of capillaries and obstruction of capillary 
flow (235, 243, 244). Moreover, pericytes were suggested as the source of MSCs from 
various human organs (245). While it is clear that not all pericytes behave as MSCs, whether 
all MSCs are pericytes awaits further investigation (246). 
 
4.1.2 Heterogeneity 
 
There is increasing evidence of a continuum of heterogeneous mural cell types along the 
microvascular tree. In particular, several pericyte subsets have been acknowledged based on 
morphology. Recent studies of the cortical angioarchitecture have identified thin-strand 
helical pericytes and mesh pericytes on capillaries and a multitude of transitional MMC 
phenotypes along the microvascular tree (Figure 5). Those include VSMC–pericyte hybrids, 
termed ensheathing pericytes, at the interface of pre-capillary arterioles and capillaries. 
Additionally, mesh pericytes with stellate morphology were identified at the interface of post-
capillary venules and capillaries (218, 247–249).  
 
 
Figure 5 | Mural cell heterogeneity and organization in the adult CNS………………………………………. 
Schematic depiction of the continuum of mural cell types along the cerebrovasculature in the mouse...………… 
Reproduced from (247).  
 
A hindering factor regarding pericyte identity is the lack of a single entirely pericyte-specific 
molecular marker. Currently used markers are not exclusively expressed by pericytes, and do 
recognize additional cell types. An example is the commonly accepted pericyte marker NG2, 
which also marks OPCs, Schwann cells and macrophages after injury (10, 250, 251). In 
addition, no molecular marker recognizes all pericytes (217, 222, 252). Importantly, other 
cells than MMCs are present in perivascular spaces, including fibroblasts, adventitial cells 
and macrophages, and challenge their proper identification (31, 247, 253, 254).  
Heterogeneity among pericytes based on differential molecular marker expression has been 
previously recognized. The most well established molecular markers expressed by capillary 
pericytes are the cell surface antigens PDGFRβ, NG2, CD13 (also known as aminopeptidase-
N) and RGS5 (248, 252, 255), also shared by other MMCs. Additional markers include the 
potassium inwardly-rectifying channel protein Kir6.1, a pore-forming subunit of ATP-
sensitive potassium channels, and SUR2. New markers enriched in capillary pericytes have 
been suggested recently (255) and include vitronectin and IFITM1. It is still debatable 
whether pericytes express αSMA, a contractile protein that marks arterial SMCs (222, 252, 
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255, 256). Nonetheless, pericytes were recently shown to express moderate-to-robust levels 
of other contractile proteins, such as desmin, calponin-2 (255) and MYL9 (257).  
Pericyte marker expression may be spatiotemporally regulated in conjunction with 
developmental stages, tissue types, pathological situations and in vitro or in vivo conditions, 
among others. Therefore, pericytes are ususally identified based on morphological 
characteristics and location (e.g., encasement by the vascular basal lamina and extension of 
cytoplasmic processes along the abluminal surface of the endothelial tube), in combination 
with at least two molecular markers (222)... …………………………………………………. 
Functional heterogeneity among pericytes, vascular SMCs and perivascular cells in general, 
might also be explained by distinct developmental origin (258). Pericytes in the face, brain, 
and thymus have a neural crest origin (259–266), whereas pericytes of the lung, gut, liver and 
heart originate from the mesothelium (222, 267–272).  
Although heterogeneity among pericytes, and mural cells in general, can be appreciated, 
whether particular subsets of pericytes play different functions under physiological conditions 
or in response to an insult is still a matter of investigation. …………………………………… 
The work presented in this thesis explores the contribution and role of a subset of pericytes in 
the context of CNS injury and disease. 
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5 PRESENT INVESTIGATION 
5.1 AIMS  
 
Paper I - To determine the cellular origin and function of fibrotic scar tissue following CNS 
injury 
 
Paper II - To investigate the therapeutic potential of reducing fibrotic scarring by a subset of 
pericytes  
 
Paper III - To investigate whether scarring by a subset of pericyte-derived cells is a 
conserved mechanism across diverse CNS lesions 
 
Paper IV - To delineate the recruitment mechanism leading to fibrotic scar tissue generation 
by a subset of pericytes  
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5.2 PAPER I - RESULTS AND DISCUSSION 
 
In the adult mammalian CNS, scar tissue that develops at sites of injury is composed of a 
fibrotic lesion core immediately surrounded by a glial scar. Before our work (Paper I), the 
cellular origin of stromal fibroblasts residing in fibrotic scar has not been addressed with 
genetic lineage tracing. In Paper I we have explored the contribution of pericytes and 
progeny in CNS scar formation after SCI by genetic fate mapping to overcome limitations 
related to injury-induced cell fate changes and shifts in marker expression. 
To genetically label and fate map a subset of pericytes in the adult mouse spinal cord, we 
made use of BAC transgenic mice expressing a tamoxifen-inducible form of Cre-
recombinase (i.e. CreERT2) under the GLAST promoter (273), in combination with a Cre-
reporter line expressing YFP (274), hereafter referred to as GLAST-CreERT2; Rosa26-YFP 
mice (Figure 6).  
 
 
 
 
 
 
 
Figure 6 | Genetic labeling of type A pericytes………………………………………………………………….. 
(A) Schematic depiction of the strategy to induce genetic……………………………………………………….  
recombination and labeling of a subset of perivascular cells lining the…………... ……………………………….  
vasculature, termed type A pericytes.……...………………………….……….……aaaaaa………………………  
(B) Type A pericytes (positive for the GLAST-CreERT2 transgene) but not ……………………………………… 
type B pericytes (negative for the GLAST-CreERT2 transgene) undergo………………………………………  
tamoxifen-mediated genetic recombination and turn on fluorescent Reporter expression.………………………  
Type A pericytes and progeny can be traced by stable and inheritable labeling with fluorescent Reporter...........… 
Adapted from (Paper IV). Image credits: Jannis Kalkitsas 
 
Upon tamoxifen-mediated genetic recombination, GLAST-expressing pericytes could be 
readily observed as YFP-positive cells lining blood vessels throughout the spinal cord 
parenchyma. Thorough characterization of the GLAST-CreERT2; Rosa26-YFP line at the 
ultrastructural level and differential marker expression revealed specific targeting of a distinct 
pericyte subpopulation, which accounts for about 10% of all PDGFRβ-expressing pericytes 
within the uninjured adult mouse spinal cord parenchyma. Pericyte heterogeneity based on 
marker expression and morphology has been recognized but somehow difficult to ascertain 
(275). We have termed the recombined subclass of pericytes labeled in the GLAST-CreERT2; 
Rosa26-YFP line, type A pericytes, and the other non-recombined subpopulation(s) of 
pericytes, as type B pericytes. Type A pericytes expressed the established pericyte markers 
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PDGFRβ and CD13, but not desmin and αSMA, found in type B pericytes. Additionally, 
some of the GLAST-positive pericytes also expressed PDGFRα. Apart from type A 
pericytes, occasional recombination was observed in association with the meningeal 
vasculature and in a minor subset of ependymal cells and white matter radial astrocytes in the 
spinal cord (30). ………………………………………………………………….…………… 
Genetic pericyte labeling in combination with SCI revealed that type A pericytes strongly 
reacted to injury by increasing in number. Recombined pericyte-derived cells proliferated 
massively and peaked at 9-14 days post injury and then decreased in number as the scar 
condensed and matured. During the wound contraction phase, type A pericyte-derived cells 
were found to transiently express the myofibroblast marker, αSMA. Interestingly, in response 
to injury, a large fraction of type A pericyte-derived cells dissociated and migrated away from 
the blood vessel wall, and gave rise to stromal fibroblasts that ultimately clustered in the core 
of the lesion and became embedded in fibrous ECM. Type A pericyte-derived cells remained 
in the lesion core for at least 7 months after SCI and were chronically surrounded by reactive 
astrocytes. Importantly, only type A pericytes, but not type B pericytes, leave the blood 
vessel wall, demonstrating functional heterogeneity among pericyte subpopulations regarding 
scar formation. As stated earlier, some type A pericytes expressed PDGFRα, a marker that is 
shared with OPCs. We have, therefore, verified whether type A pericytes gave rise to 
oligodendrocytes or OPCs after SCI. Fate mapping of type A pericytes, including PDGFRα-
positive cells, extending several months after injury, showed no contribution to 
oligodendrocyte-lineage cells. On the other hand, co-targeting of scar-forming pericytes and 
OPCs was reported in recent lineage tracing studies employing PDGFRα-CreERT2 lines (10) 
and needs to be taken into consideration when interpreting results (276).  
In summary, we showed that a discrete subpopulation of perivascular cells lining the 
vasculature, termed type A pericytes, are the primary source of stromal fibroblasts that form 
the core of the chronic CNS scar in the injured mouse spinal cord (Figure 7). These 
observations are in line with a pericyte/perivascular fibroblast origin of fibrotic tissue in 
peripheral organ fibrosis (208–213, 277, 278). 
  
  22 
Figure 7 | Type A pericyte-derived scarring after SCI......................................................................……………. 
In the uninjured CNS, type A pericytes represent a small subpopulation of perivascular cells associated with the 
vasculature within the grey and white matter. After injury, type A pericytes invade the lesion site together with 
angiogenic vessels, proliferate, dissociate from the vascular wall and gather at the lesion site embedded in 
fibrous ECM. During the wound contraction phase, type A pericyte progeny temporarily turn on αSMA 
expression. By the end of the wound closure process, type A pericyte-derived scar tissue occupies the lesion core 
and is bordered by reactive astrocytes. As the scar matures, a sharp border is established and segregates the glial 
and fibrotic compartments of the scar. With time, the scar further condenses and reduces in size but remains 
chronically. 
Reproduced from (79).  
 
Following injury, we observed that nearly all scar-participating pericyte-derived cells have 
been generated through proliferation. To investigate the role of pericyte-derived scarring 
following SCI, we made use of a genetic tool that allowed cell-specific and inducible 
inhibition of the generation of type A pericyte progeny by specifically blocking injury-
induced proliferation. This was achieved by creating a new transgenic mouse line that result 
from crossing GLAST-CreERT2; Rosa26-YFP mice with ‘Rasless’ conditional knockout 
mice, hereafter referred to as GLAST-CreERT2; Rasless; Rosa26-YFP mice (Figure 8). The 
‘Rasless’ line (279) is a complete knockout for the H-ras and N-ras genes and a conditional 
knockout for the K-ras gene, important players in mitogenic signaling and proliferation. 
Tamoxifen-induced recombination in GLAST-CreERT2; rasless; Rosa26-YFP mice resulted 
in the loss of H-ras, N-ras and K-ras genes specifically in type A pericytes and conferred less 
proliferative capacity to this population of cells upon injury. As control, we used animals 
with identical genotype that were treated with vehicle and, therefore, did not undergo Cre-
mediated recombination. 
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Figure 8 | Genetic strategy to block the generation of progeny by type A pericytes………………...……….. 
Adapted from (280).  
 
Following SCI, control animals preserved intact type A pericyte-derived scarring and 
presented prominently packed scars with a dense lesion core composed of PDGFRβ-
expressing fibroblast-like cells enclosed in fibronectin, and lined by reactive astrocytes. 
Conversely, in animals presenting nearly complete inhibition of type A pericyte proliferation 
(strong inhibition, Figure 9), fibrotic scarring was abolished and the lesion site failed to seal. 
These animals developed an open tissue defect at the site of the injury. These observations 
demonstrated that type A pericyte-derived cells are essential to patch off the injured tissue 
and are required for the reestablishment of tissue integrity. Interestingly, in cases of 
incomplete Cre-mediated inhibition of type A pericyte proliferation (moderate inhibition, 
Figure 9), fibrotic scarring was reduced, as seen by a less dense scar core presenting 
significantly fewer PDGFRβ-expressing stromal cells and reduced fibronectin deposition, but 
allowed simultaneous sealing of the wound. Moderate inhibition of type A pericyte 
proliferation thus represents an attractive scenario to assess the influence of pericyte-derived 
fibrotic scarring on axonal regeneration and functional recovery (Paper II). 
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Figure 9 | Inhibition of type A pericyte proliferation results in reduced fibrotic scar tissue generation 
Strong reduction of type A pericyte proliferation abolishes fibrotic scar tissue generation and results in an 
unsealed lesion. Conversely, moderate inhibition of type A pericyte proliferation allows wound closure and leads 
to reduced fibrotic scar tissue generation.…………………………………………………………………… 
Reproduced from (79). 
 
5.3 PAPER II - RESULTS AND DISCUSSION 
 
The identification of type A pericytes as the main source of scar-forming stromal fibroblatsts 
contributing to fibrotic tissue generation in the injured spinal cord (Paper I) enabled us to 
selectively address how pericyte-derived fibrotic scarring influences axon regeneration and 
functional recovery following SCI.  
In Paper II, we employed the same inducible and cell type specific genetic strategy to 
render scar-forming type A pericytes unable to proliferate (i.e. GLAST-CreERT2; rasless; 
Rosa26-YFP mice). We showed, by RNA-sequencing, that the lesion enviroment following a 
dorsal hemisection SCI was less fibrotic when pericyte-derived scarring was attenuated 
(moderate inhibition, Figure 9) compared to conditions of intact pericyte-derived scarring, in 
which excessive deposition of fibrous ECM could be appreciated. Animals with nearly 
complete ablation of pericyte proliferation, leading to impaired sealing of the lesioned tissue 
(strong inhibition, Figure 9), were excluded from the analysis. Moderate reduction of type A 
pericyte-derived fibrosis led to decreased axonal dieback and significantly increasead 
regeneration of descending CST axons into and beyond the lesion site, after SCI. As 
expected, control animals with intact pericyte-derived scarring showed densely packed 
fibrotic scars with minimal to no regeneration of CST axons beyond the lesion site. Similarly, 
increased density of RST axons innervating the spinal cord ventral horn caudal to injury was 
detected in animals with reduced pericyte-derived scarring when compared to control 
animals. Using optogenetic stimulation of the CST (281–284) combined with 
electrophysiology, we validated that CST regenerated fibers synaptically integrated into the 
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local spinal circuitry below the lesion site. In addition, improved recovery of sensorimotor 
function in a horizontal ladder-walking test (285), catwalk-aided gait analysis and 
optogenetic motor-task was observed when pericyte-derived scarring was attenuated (Figure 
10).  
Figure 10 | Genetic labeling of type A pericytes………………………………………………………………… 
Attenuation of type A pericyte-derived scarring promotes axon regeneration and functional recovery after SCI.. 
Regenerated fibers make functional synapses with local spinal neurons below the lesion site.…...……………….  
Reproduced from (280).  
 
In general, sensory axons possess greater regenerative ability than retinal ganglion cell and 
central motor axons (286, 287). The fibrotic matrix that develops at the injury site can be 
penetrated to a certain extent by some classes of re-growing ascending sensory axons, but not 
by re-growing descending motor axons (288). It remains to be tested whether attenuation of 
pericyte-derived scarring favors injured sensory axons to cross lesions scars and regenerate 
distally. In contrast to CST axons, which are myelinated (289–291), serotonergic RST axons 
are unmyelinated (292, 293) in rodents. Additionally, serotonergic axons exhibit minimal 
axonal dieback and enhanced ability to regenerate or sprout after CNS injury, when 
compared to CST axons, which are very refractory to regeneration (193, 294–296). We 
decided to study regeneration of serotonergic RST axons because of their relevance in 
modulating the activity of spinal motor systems (189), and regeneration of the CST due to 
its significance in clinical neurorehabilitation. We observed that attenuation of pericyte-
derived scarring reduced fibrosis and modified the lesion environment, facilitating RST and 
CST axon regeneration, and promoted sensorimotor recovery after SCI. Interestingly, 
improved performance in sensorimotor behavioral tasks was positively correlated to RST 
and CST axon regeneration, suggesting that regenerated fibers may play a role in behavioral 
recovery, probably through indirect relay-circuits (297–300). Our observations that fibrotic 
scar tissue inhibited axonal regeneration are in agreement with other reports. In addition to 
enhancing the capacity of axons to grow, microtubule-stabilizing drugs were shown to 
decrease fibrotic scarring and promote regeneration of RST and sensory axons after SCI (139, 
201, 301, 302). Additionally, when stimulating the intrinsic growth capacity of neurons by 
PTEN deletion, axon regeneration occurs along glial bridges and in regions devoid of fibrotic 
tissue (106, 107). Further studies will be required to investigate whether upregulation of 
genes associated with axon outgrowth, cell protection, and neural development occurs in 
cortical pyramidal neurons or hindbrain raphespinal neurons upon reduction of pericyte-
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derived scarring, as suggested by others after anti-scarring treatment (303, 304) or CSPG 
modulation with chondroitinase ABC (305, 306). 
We showed that, in conditions of intact pericyte-derived scarring, only a small percentage of 
CST fibers reached the lesion core, making contact with pericyte-derived cells, at sub-acute 
stages after SCI. Since a glial scar rapidly flanked the injured tissue, most of the CST fibers 
contacted GFAP- and NG2-expressing glia and, to a less extent, CD68-positive 
microglia/macrophages. It is intuitive to think that pericyte-derived fibrotic tissue would only 
represent a molecular and physical barrier to regeneration of severed axons that are able to 
overcome macrophage-mediated axonal dieback (307), penetrate the glial-fibrotic scar 
interface, and finally reach the lesion core. However, since pericyte-derived cells intermingle 
with macrophages in the lesion core of the scar and participate in the establishment of a sharp 
border with glial cells, alterations in the fibrotic compartment of the scar will likely influence 
the behavior of other scar-participating cells. It is well appreciated that prevention, deletion 
or attenuation of ependymal cell and astrocyte scarring results in impaired functional 
recovery that is coupled to increased neurotoxic inflammation, augmented fibrotic scarring 
and enlargement of the lesion core, and decreased axon regeneration (35, 41, 43, 100, 308). 
We observed reduced astrogliosis and inflammation, but no significant changes in the 
number of OPCs, when pericyte-derived scarring was attenuated after SCI. These changes 
may have contributed positively to the improved axonal regeneration and functional 
recovery observed in our study. Reports by others have backed up this notion. For example, 
animals with reduced glial and fibrous scarring and a dampened inflammatory response show 
improved axon regeneration coupled to, in some cases, improved recovery after SCI (76, 81, 
88, 207, 309–311). Similarly, disrupting reactive astrocyte-collagen I interactions, likely 
produced by pericyte-derived fibrotic cells, attenuates glial scarring and leads to improved 
axon regrowth and functional recovery after SCI (87). Conversely, excessive fibrotic scar 
formation, with pronounced deposition of fibronectin, laminin and collagen IV, and increased 
expression of CSPGs at the lesion site are correlated to worsened locomotor performance 
after SCI (312). ..……………………………………………………………………………  
Scar modulation treatment by inhibition of collagen IV biosynthesis decreases basement 
membrane deposition and promotes axon regeneration after brain injury when applied 
acutely and early sub-acutely after injury (313). However, when administered at late sub-
acute or chronic stages after injury, it fails to decrease matrix deposition and does not 
promote regeneration of axons across the injury site. These observations show that 
interfering with collagen IV biosynthesis needs to be completed at early stages after injury, 
when fibrotic scar tissue is being generated. It suggests that, at later stages, pericyte-derived 
scar tissue has been already formed and, is, therefore, insensitive to inhibition of collagen 
IV biosynthesis. ……………………………………………………………………………. 
A recent study showed that ablation of dividing NG2-expressing cells after SCI led to loss 
of integrity of the glial scar, prevented injury-induced angiogenesis and abolished 
fibrotic scar formation, with concomitant increase in axon regrowth. These changes resulted 
in persistent edema and hemorrhage, and animals displayed worsened functional recovery 
  27 
after SCI (75). The NG2 promotor targets both OPCs and pericytes and it is not possible to 
distinguish whether the impaired functional recovery and morphological changes in scar 
tissue observed after ablation of proliferating NG2-expressing cells are due to selective 
killing of NG2-expressing pericytes or NG2-expressing glia, or both. In another study, 
specific ablation of capillary pericytes co-expressing NG2 and PDGFRβ with diphtheria 
toxin caused BBB breakdown, accompanied by disturbances in blood flow and neuronal 
loss (242). In our study (280), we selectively targeted type A pericytes and not a mixed 
population of cells types. Additionally, we did not ablate proliferating type A pericytes. 
Instead, employing GLAST-Rasless-YFP mice, we mediated cell-specific and inducible 
inhibition of type A pericyte proliferation, and, therefore, noticed a reduction in the 
generation of injury-responsive type A pericyte-derived progeny. Importantly, the vasculature 
outside the lesion area remained unaffected (30).  
As recognized for astrocytes (35, 43, 100) and ependymal cells (41, 308), pericyte-derived 
scarring is necessary to preserve tissue integrity at acute and sub-acute stages after trauma, 
but represents an absolute barrier for axon regrowth at more chronic stages after SCI. We 
conclude that moderate reduction of type A pericyte-derived scarring promotes axon 
regeneration and functional recovery after SCI. 
 
5.4 PAPER III - RESULTS AND DISCUSSION 
 
Traumatic injuries to the brain and spinal cord, as well as, inflammatory demyelinating 
disease result in the formation of a permanent scar that exhibits a fibrotic and glial 
component. Scarring, accompanied by extensive vascular remodeling, can also be appreciated 
in brain tumors and after transient interruption of blood flow to the brain, followed by 
reperfusion (Figure 3) (123). Multiple cell types, including meningeal and perivascular 
fibroblasts, mesenchymal perivascular cells, fibrocytes and pericytes, have been suggested to 
contribute to ECM-producing stromal fibroblasts residing in fibrotic CNS scar tissue (3, 30, 
151, 153–156, 158–160, 172, 199, 31, 202, 81, 88, 121, 129, 131, 143, 147). However, no 
genetic fate mapping has been employed in those studies, making it difficult to ascertain the 
cellular origin of fibrotic scarring. 
In Paper III we investigated the contribution of type A pericytes to scar-forming fibroblasts 
following penetrating and non-penetrating SCI, stab lesions to the brain, EAE, ischemic 
stroke and brain cancer. As previously, we employed GLAST-CreERT2;R26R-YFP mice to 
lineage-trace type A pericytes in the adult mouse CNS (Figure 6). In addition to the spinal 
cord, type A pericytes, sharing similar marker expression and comprising about 10% of all 
PDGFRβ-expressing cells, could be identified in the uninjured brain (Figure 11A). 
We showed that type A pericytes are the main source of scar-forming fibroblasts that reside 
in fibrotic scar tissue generated following penetrating and non-penetrating traumatic SCI, 
cortico-striatal stab lesions and EAE. In response to injury, pericyte-derived cells migrated 
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away from the vascular wall and formed the fibrotic core of the lesion, bordered by reactive 
astrocytes (Figure 11B).……………………………………………………………………..  
Tumor vessels are known to be leaky and tortuous, and present low pericyte coverage. As 
expected, type A pericyte coverage was decreased in tumor-associated vessels, in a GBM 
tumor model. Nonetheless, type A pericyte-derived cells dissociated from the vascular wall 
and contributed to tumor-associated stromal fibroblasts (Figure 11C).………………………. 
The ischemic lesion core that developed following transient MCAO-induced striatal ischemia 
(striatal stroke) underwent profound vascular remodeling but lacked typical stromal 
fibroblasts, readily found in fibrotic scar tissue generated after SCI, TBI and EAE. Therefore, 
type A pericytes expand and contribute to increased vessel coverage, but were rarely detected 
away from the vascular wall after striatal strokes (Figure 11D). Interestingly, PDGFRβ-
expressing stromal fibroblasts cells are promptly observed following cortico-striatal ischemic 
strokes (121). These observations suggest that the location and magnitude of the ischemic 
insult dictates the generation of scar-forming fibroblasts. It remains to be evaluated whether 
type A pericytes contribute to stromal fibroblasts following cortico-striatal ischemic strokes. 
 
Figure 11 | Pericyte-derived fibrotic scar tissue formation is a conserved mechanism in response to diverse 
CNS lesions………………………………………………………………………………………………………..  
Schematic illustration depicting the contribution of type A pericyte-derived cells to diverse CNS lesions. In the 
uninjured CNS, type A pericytes are found associated with the blood vessel wall (A). After penetrating and non-
penetrating SCI, cortico-striatal stab lesions and EAE, type A pericytes give rise to progeny that dissociate from 
the vascular wall and cluster at the core of the lesion, making up the fibrotic scar (B). The vasculature of 
glioblastoma tumors shows reduced coverage by type A pericytes. Type A pericytes and progeny contribute to 
stromal fibroblasts in glioblastoma tumors (C). Following ischemic stroke confined to the striatum, type A 
pericytes increase in number but remain associated with the vascular wall (D). …………….………………….. 
From (Paper III). Image credits: Jannis Kalkitsas 
 
As appreciated in Papers II and IV the response of type A pericyte to CNS injury is closely 
linked to inflammation. Attenuation of type A pericyte-derived scarring is accompanied by 
reduced inflammation after SCI (Paper II). The contrary is also true, and preventing CCR2-
dependent infiltration of monocyte-derived macrophages into the injured CNS results in 
reduced fibrotic scar tissue generation following SCI (Paper IV; (76)). We postulated that 
similar crosstalk between macrophages and pericytes takes place after TBI, EAE and GBM. 
However, following an ischemic striatal stroke, there is evidence suggesting that microglia 
activation predominates over macrophage infiltration and that infiltrating peripherally-
derived macrophages acquire a microglial-like phenotype once in the infarcted tissue (314). 
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Additionally, neutrophils are mainly recruited from nearby skull bone marrow and not from 
throughout the whole body, as commonly accepted, following ischemic stroke (315, 316). 
Therefore, differences in the activation and recruitment of inflammatory and immune cells 
may also underlie the lack of type A pericyte dissociation from the vascular wall after stroke. 
Our results showed that only large lesions to the brain, as cortico-striatal stab wounds, 
elicited fibrotic tissue generation and type A pericyte-derived scarring. Stabs lesions 
restricted to the cerebral cortex were accompanied by gliosis but were poor at producing 
fibrotic tissue, as indicated by the emergence of low or no fibroblast-like cells after injury. 
Therefore, type A pericyte-derived scarring was limited under these conditions. This is in 
agreement with a report revealing no increase in Col1a1-expressing fibroblasts following a 
cortical stab wound and, therefore, no participation of Tbx18-expressing mural cells 
(pericytes and vascular smooth muscle cells) in the injury response (317). Reevaluation of 
the contribution of Tbx18-expressing mural cells in the context of larger brain lesions, such 
as cortico-striatal stab lesions, should clarify the role of pericytes in fibrotic scar tissue 
formation. Recent data suggests that all vessel-associated perivascular cells express Tbx18 
(255, 318). Nonetheless, type A pericytes and Tbx18-expressing mural cells could still 
represent two functionally different perivascular populations, with scar formation properties 
being restricted to type A pericytes. 
Fibroblasts migrating from the damaged dura mater meningeal layer (144, 150, 151) have for 
long been considered the primary source of fibrotic scar tissue in penetrating models of SCI. 
Since, in addition to type A pericytes, occasional recombination occurs in cells associated 
with the meningeal vasculature in the uninjured brain and spinal cord of GLAST-
CreERT2;R26R-YFP animals (30), there is a chance that dura mater fibroblasts contribute to 
the fibrotic scar, following penetrating SCI. However, even following non-penetrating spinal 
injuries, which do not breach the dura mater and limit the invasion of dura mater-derived 
fibroblasts into the lesion site (e.g. contusion, clip compression and crush injuries (28, 106, 
107, 136, 301, 319, 320)), extensive fibrotic tissue generation can be appreciated (Figure 
3A,E), suggesting an alternative origin of scar-forming fibroblasts...………………………….  
We compared the contribution of type A pericyte-derived scarring to penetrating and non-
penetrating spinal lesions, by employing a DFI (30, 38, 42) and a complete crush SCI model 
(106, 107), respectively. In case the fibrotic scar tissue is derived from recombined dural 
meninges, we would observe scar-forming fibroblasts recombined following DFI, but little 
or no scar-forming fibroblasts recombined after crush SCI. Conversely, if the majority of 
scar-participating fibroblasts originate from type A pericytes, we would observe similar 
numbers of recombined fibroblasts after DFI and crush SCI. Indeed, we found that the 
majority of stromal fibroblasts that compose the fibrotic lesion core were recombined 
following both DFI and spinal crush, and therefore derived from type A pericytes. These 
results suggested that type A pericytes, rather than dura mater meningeal fibroblasts, are the 
major source of scar-forming fibroblasts following penetrating and non-penetrating injuries to 
the spinal cord, shifting the origin of fibrotic scarring from meninges to the vasculature. 
However, we could not rule out that both meningeal fibroblasts and type A pericytes 
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contribute to stromal fibroblasts in penetrating spinal injuries. Future studies, employing a 
lentivirus-based technique to label meninges and meningeal substructures (321), could 
elucidate the role of meningeal-derived scarring after SCI.  … ……………………….………  
Col1a1-expressing perivascular fibroblasts were proposed to function as the primary source 
of scar-forming fibroblasts following contusive SCI in mice (31). Since no fate mapping of 
Col1a1 cells has been employed in this study, the origin of scar-participating fibroblasts 
could not be pinpointed. Additional experiments are required to investigate whether type A 
pericyte-derived fibroblasts and Col1a1-expressing fibroblasts represent the same population. 
Following SCI, reactive astrocytes interacted with type A pericyte-derived fibrotic cells to 
form a sharp lesion border, separating the glial and fibrotic compartments of the scar. Similar 
segregation of fibrotic and glial components occurred when GFAP-positive glial processes 
bridged the lesion site, in regions devoid of pericyte-derived cells. Interestingly, type A 
pericyte-derived cells apposed to reactive glia at the glial-fibrotic lesion border exhibited a 
different morphology and arranged differently than type A pericyte-derived cells that 
intermingled with immune cells in the inner core of the fibrotic scar. It remains to be explored 
whether these two morphologically distinct populations of type A pericyte-derived cells are 
functionally different.  
Type A pericytes are the major source of scar-forming fibroblasts following chronic EAE. 
Further studies will be required to investigate whether pericyte-derived scarring resolves once 
a lesion gets remyelinated. This could be tested in a relapse/remitting EAE model (322, 323). 
Additionally, chemically-induced demyelination models, such as LPC-induced focal 
demyelination (324) and cuprizone-mediated systemic demyelination (325, 326), with 
established dynamics of de- and re-myelination (324, 327, 328), could prove useful in 
answering this question. 
Rats and humans, but not mice, are prone to develop fluid-filled cysts (cavitation) after 
contusive spinal injuries. Nonetheless, fibrous connective scar tissue enriched in ECM 
deposits and inflammatory cells forms at the lesion site after traumatic SCI in humans, 
specially after crush, compression and lacerating injuries (3, 62, 137, 139, 140). Interestingly, 
fibrotic scarring still occurs in contusion injuries containing multiple hemorrhagic and 
necrotic regions in humans (Paper III, (3, 62, 137). Corroborating our observations in the 
mouse, we found regions of non-neural scar tissue enriched in PDGFRβ-expressing stromal 
fibroblasts and delimited by reactive glia following traumatic SCI in humans. Additionally, 
perivascular aggregates of PDGFRβ–expressing stromal cells surrounded by reactive glia 
were observed in spinal cords of individuals with active MS, similar to what has been 
reported in MS brain lesions (129). In agreement with our observations following MCAO-
induced ischemia in the mouse, PDGFRβ-expressing cells associated with the vasculature 
and exhibited characteristics of pericytes in the ischemic lesion core of stroke patients. 
Likewise, PDGFRβ-expressing pericytes remained in close association with blood vessels in 
the stroma of aggressive grade IV human GBM tumors.……………………………………. 
Pericytes and perivascular fibroblasts have been identified as the main source of 
(myo)fibroblasts in peripheral organ fibrosis (208–213, 277, 278), attributing functional 
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similarities to pericytes in the CNS and peripheral organs...………………………………… 
In summary, we revealed that pericyte-derived fibrotic scarring is conserved in response to 
different CNS lesions, with the exception of striatal stroke. Humans also generate fibrotic 
scar tissue enriched in stromal fibroblasts after traumatic SCI and MS. 
 
5.5 PAPER IV - RESULTS AND DISCUSSION 
 
Differences in the molecular and cellular composition of distinct CNS regions may impact on 
the injury response (329). While studying the contribution of type A pericytes to a vast 
number of CNS insults we noticed that lesions leading to greater white matter damage had 
the tendency to generate larger amounts of fibrotic scar tissue. Namely, cortical stab wounds 
were poor at triggering fibrotic scar tissue formation (317), but deeper cortico-striatal stab 
lesions, extending through the corpus callosum white matter tract, potentiated pericyte 
recruitment and generation of fibrotic scar tissue. Similarly, larger ischemic insults, affecting 
both cortical and subcortical areas and damaging the corpus callosum white matter (121), or 
subcortical white matter infarction (330), showed extensive fibrotic scar tissue generation 
with large numbers of stromal fibroblasts and perivascular cells away from the vascular wall, 
in comparison to ischemic strokes restricted to the striatum (Paper III). Similarly, white 
matter injury was found to influence the behavior and reactivity of grey matter cellular 
components (331). These observations suggested that the extent of white matter damage may 
impact and titer pericyte-derived fibrotic responses. Therefore, in Paper IV, we explored the 
role of white matter damage and myelin in type A pericyte recruitment following CNS injury.  
We employed GLAST-CreERT2 mice (30, 273, 280) crossed to a Rosa26-tdTomato Cre-
reporter line (332), hereafter referred to as GLAST-CreERT2;Rosa26-tdTomato, to fate map 
type A pericytes and progeny and started by investigating regional differences in pericyte-
derived fibrotic scarring following discrete lesions to the spinal cord grey or white matter. 
Corroborating our initial hypothesis, these experiments showed that white matter lesions 
trigger a greater and more widespread recruitment of type A pericyte progeny when 
compared to grey matter lesions. Similar differences in white versus grey matter responses 
have been reported for other cells types. Following SCI, the density of microglia/infiltrating 
monocyte-derived macrophages increases by 40-fold in lesioned white matter against 9-fold 
in lesioned grey matter (333). Following discrete mechanical injuries, a larger inflammatory 
response in white matter compared to grey matter is observed within both the brain and 
spinal cord (334). Similarly, microglia proliferation is increased in the white matter 
compared to grey matter following cerebral stab lesions affecting the grey and white matter 
(331). 
In addition to other molecular and cellular differences, white matter regions are enriched 
in their myelin and mature oligodendrocyte content when compared to grey matter 
regions. We subsequently injected LPC, a membrane-solubilizing agent that preferentially 
targets myelin-producing cells and causes minimal axonal damage (324), into the spinal cord 
white matter and found that focal myelin damage per se, uncoupled to a traumatic injury or 
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invasive mechanical tissue damage (e.g. spinal lesion), is sufficient to induce pericyte-derived 
scarring.  
We then tested whether myelin itself, independent of chemically-mediated degeneration, was 
capable of initiating a fibrotic response. We found that injection of purified myelin into the 
uninjured spinal cord grey matter, but not cell membranes in general (e.g. isolated liver 
membranes), was able to recruit pericyte progeny from the vascular wall. When studying this 
process in more detail we observed that intraspinal myelin injection recapitulated most 
temporal and spatial aspects of CNS scar formation, including activation of microglia, 
infiltration of peripherally-derived macrophages, clearance of myelin debris by phagocytic 
cells, pericyte-derived cell recruitment from the blood vessel wall and fibrotic scar formation, 
followed by astrocyte scarring at later stages. Pericyte-derived cells intermingling with Mac2-
expressing cells formed the fibrotic core of the lesion and were immediately surrounded by 
reactive astrocytes, as seen after SCI (30, 280). In contrast, intraspinal injection of liver 
membranes triggered activation of microglia and gliosis but elicited nearly no recruitment of 
pericyte progeny and only minor infiltration of peripheral macrophages. Although it is clear 
that monocyte-derived macrophages are vital for clearance of myelin debris following CNS 
injury (335, 336), the same process does not take place for clearing off liver membranes.  Our 
results showed that cellular uptake and clearance of liver membranes was initially slow, but 
activated microglia were capable on their own to phagocytose non-CNS membrane 
components, suggesting that microglia failed to recruit peripherally-derived macrophages to 
assist in adequate and time efficient debris clearance (337). In agreement with previous 
observations recognizing activated neuroinflammatory microglia as potent inducers of 
astrocyte reactivity and polarization (90, 338), we detected an astrogliotic response following 
intraspinal injection of liver membranes. 
Interestingly, we noticed that a sharp increase in the number of Mac2-expressing cells, 
confirmed in subsequent experiments to correspond to the entry of peripherally-derived 
macrophages into the CNS, was accompanied by activation and recruitment of pericyte 
progeny from the vascular wall, starting at 3 days and peaking at 5 days post intraspinal 
myelin injection. Additionally, we found that the area covered by Mac2-expressing cells 
following CNS insults (e.g. discrete grey and white matter spinal lesions and intraspinal LPC 
or myelin injections) positively correlated to the extent of pericyte-derived scarring. We 
therefore examined whether recruitment of pericyte progeny was dependent on the infiltration 
of monocyte-derived macrophages. In mice lacking both alleles of CCR2 (CCR2-/-), a 
receptor that is required for the infiltration of monocyte-derived macrophages into the 
inflammed CNS (336), recruitment of pericyte-derived cells was either abolished or 
significantly reduced following instraspinal injection of myelin or complete crush spinal cord 
injury, respectively, when compared to mice heterozygous for the CCR2 null alleles (CCR2+/-
). A recent study proposed that endothelial cells are capable of engulfing and degrading 
myelin, and regulate the recruitment and activation of macrophages, angiogenesis and 
fibrosis after SCI and EAE (339, 340). Additional work is needed to reveal how this process 
regulates type A pericyte recruitment in CNS injury. 
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After confirming that myelin acts as a potent trigger of fibrotic pericyte responses, a process 
that is dependent on and titrated by the extravasation of monocyte-derived macrophages, we 
set out to dissect which myelin-associated proteins are involved in the recruitment of 
monocytes and pericyte-derived cells after CNS insult. We showed that structural myelin 
proteins such as PLP and MBP did not induce recruitment of pericyte progeny nor Mac2-
positive cells following intraspinal injection. Next we tested myelin membrane proteins with 
extracellular domains capable of interacting with immune cells. We started by investigating 
the effect of Nogo because microglia and macrophages were shown to express Nogo 
receptors (341, 342) and reduced recruitment of neutrophils and monocytes to sites of 
inflammation are detected in mice lacking Nogo-A/B (343). Nogo contains two extracellular 
domains, Nogo-66 and Nogo-A-Δ20, implicated in axon growth inhibitory effects via distinct 
receptors (185). Intaspinal injection of a Nogo-A-Δ20 peptide sequence (aa544-725), specific 
to Nogo-A (344), into the spinal cord grey matter did not trigger robust recruitment of Mac2-
positive cells nor fibrotic pericyte progeny. Conversely, injection of a Nogo-66 peptide 
sequence (aa1026-1091), common to all Nogo isoforms (344), mediated extensive 
recruitment of Mac2-expressing cells and pericyte-derived cells. Additionally, Nogo has been 
implicated as a regulator of vascular remodelling (345, 346), Nogo-A has been shown to 
inhibit developmental CNS angiogenesis (347) and blockage of Nogo-A pathway promotes 
vascular growth and maturation, and functional recovery after stroke (348). We therefore 
injected a peptide sequence corresponding to a region of the NogoA/B protein linked to 
vascular remodelling (aa 1-172) (349) into the uninjured spinal cord grey matter and found 
minor recruitment of pericyte-derived cells and Mac2-expressing cells. 
We then explored the ability of MAG and OMgp, myelin-associated proteins involved in 
axon growth inhibition that also bind the Nogo-66 receptor (NgR1) (185), to trigger 
recruitment of pericyte-derived scarring and found widespread recruitment of Mac2-
expressing cells and scar-forming pericytes. These experiments demonstrated that individual 
exposure of uninjured spinal cord to Nogo-66, MAG and OMgp is sufficient to induce 
fibrotic scarring. To investigate if endogenous myelin-associated proteins play a role in 
fibrotic scar tissue generation, we performed a complete crush SCI in mice lacking all 
known Nogo isoforms, MAG and OMgp (Nogo-, MAG-, and OMgp- null mutant mice) 
(350). We found that the lesion core volume and fibrotic scar tissue generation (Mac2-
positive and PDGFRβ-expressing fibrotic cells) were reduced in Nogo-, MAG- and OMgp-
single knockout mice and triple knockout mice (Mag-/-;Nogo-/-;Omgp-/-) in comparison to 
control triple heterozygous mice (Mag+/-;Nogo+/-;Omgp+/-), 7 days after SCI. In line with 
these results, NogoA/B deletion was found to reduce liver fibrosis (351, 352).  
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In summary, we highlight the role of three well known axon growth inhibitory proteins 
associated with myelin in recruiting peripherally-derived macrophages and type A pericyte-
derived progeny that contribute to fibrotic scar tissue formation after CNS injury (Figure 12). 
We hypothesized that, in addition to their known effects in alleviating axon growth inhibition, 
therapeutic agents interfering with Nogo-A signaling (353–361) or blocking the interaction of 
NgR1 with its ligands (362–366), may reduce fibrotic scarring, and contribute to the 
neuroregenerative effects and improved functional recovery perceived after therapy. 
 
 
Figure 12 | The myelin-associated protein Nogo, MAG and OMgp induce fibrosis after CNS injury……… 
Myelin damage leads to recruitment of type A pericyte-derived progeny and scar formation, a process that is 
dependent on the infiltration of peripherally-derived macrophages...……………………………………………..  
From (Paper IV). Image credits: Jannis Kalkitsas 
 
Following SCI in humans (140, 367–369) and rodents (10, 370, 371), endogenous Schwann 
cells, myelinating cells of the PNS, invade the lesioned spinal cord and the CNS is exposed to 
peripheral myelin. It remains to be tested whether fibrotic scarring is triggered by CNS 
exposure to PNS myelin. Similarly to the CNS, MAG and OMgp are present in PNS myelin 
(372–376) and may, in fact, recruit peripherally-derived macrophages and pericyte-derived 
fibrotic tissue. Additionally, it would be valuable to investigate whether proteins specific to 
PNS myelin, such P0 glycoprotein, the major protein component of PNS myelin (377), and 
PMP-22 glycoprotein (378), may also play a role in the generation of fibrotic scar tissue 
following SCI. MBP is also expressed by PNS myelin (379, 380) but, as we have shown in 
the CNS, is not expected to contribute to recruitment of fibrotic tissue. Likewise, PLP, the 
major CNS myelin protein constituent and only marginally expressed in PNS myelin (72, 
376, 381), is neither expected to cause fibrotic tissue generation, as we demonstrated in the 
CNS.  
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As revealed by our current and previous experiments (280), the crosstalk between 
microglia/macrophages and stromal fibroblasts in neuroinflammatory, demyelinating and 
fibrotic diseases, including MS, TBI and SCI, has become increasingly appreciated (76, 81, 
88, 206, 207, 311, 382, 383). It would be of great value to further validate how pericytes 
respond to an insult in the absence of an inflammatory component. In contrast to LPC-
induced focal demyelination, that involves a strong inflammatory response, cuprizone-
mediated systemic demyelination will enable studying pericyte-derived scarring 
throughout multiple brain regions and optic nerve, but sparing the spinal cord (384), in 
the context of non-inflammatory-mediated demyelination, because the BBB integrity is 
maintained after cuprizone treatment (328). Additionally, Cre-loxP-mediated conditional 
deletion of NgR1 (385) in immune cells could be employed to unequivocally verify whether 
pericyte-derived scarring is triggered by binding of myelin-associated proteins to NgR1 in 
microglia/macrophages. Likewise, additional work employing strategies that enable 
selective manipulation of microglia, e.g. Tmem119-CreERT2 (386–388) and Cx3cr1-
CreER lines (389) crossed to mice carrying a Cre-dependent human diphtheria toxin 
receptor, iDTR (390), is needed to elucidate the role of microglia activation in pericyte 
recruitment and complement our current knowledge on fibrotic scar tissue formation after 
CNS injury (14, 77, 391).  
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6 CONCLUDING REMARKS AND FUTURE 
PERSPECTIVES 
 
Response to injury is an intricate process orchestrated by multiple interacting cells types that 
work in consonance to reestablish tissue integrity. In the CNS, this wound healing process 
results in the formation of a scar, which encapsulates and prevents further spread of the 
damage, but simultaneously in chronic stages prevents neuroplasticity and functional 
recovery. The ultimate purpose of regenerative medicine is to achieve tissue repair and 
restoration of function without scarring. It is therefore imperative to understand the etiology 
of scar-forming fibroblasts, matrix-producing cells that are critically involved in the 
generation of scar tissue, in the context of CNS injury and disease (392).  
This thesis demonstrates a conserved and pivotal role for a subset of pericytes as the main 
cellular source of stromal fibroblasts that compose fibrotic scar tissue in response to diverse 
CNS lesions. This group of perivascular cells, found in close association with the vasculature 
under homeostatic conditions, was coined type A pericytes, in order to distinguish them from 
other pericytes that do not exhibit scar-forming properties. Future single-cell RNA-seq and 
proteomic studies in combination with genetic lineage tracing, should contribute to a better 
understanding of different pericyte subtypes and their contribution to fibrosis. 
We have collected evidence that pericyte-derived scarring plays a key role in wound healing 
and the restoration of tissue integrity after acute tissue injury. As recognized for scar-forming 
astrocytes (43, 90, 146, 393), activated microglia and infiltrating monocyte-derived 
macrophages (78, 115, 116, 337, 394–399), pericyte-derived cells engage in seemingly dual 
opposing roles: on the one hand they are required to seal off the injury site, as lesions failed 
to close when pericyte-derived scarring was nearly completely abolished; on the other hand, 
pericyte-derived scar tissue is not cleared off and contributes to axon regeneration failure and 
impaired functional recovery after CNS injury. We highlight that fibrotic scar tissue is 
amenable to manipulation, as moderate reduction of pericyte-derived scarring improves 
axon regeneration and functional recovery after SCI. We also demonstrate that fibroblast-
lineage cells are present in non-neural, fibrotic scar tissue in human pathology, indicating 
the therapeutic relevance of the studies. Interestingly, myelin damage and myelin-
associated proteins are able to trigger recruitment of scar-forming pericytes and CNS scar 
formation, a process that is dependent on the infiltration of peripherally-derived 
macrophages. Deletion of three well-established axon growth inhibitory myelin-associated 
proteins reduces fibrotic scarring, highlighting the crosstalk between myelin debris, 
inflammatory cells and fibrotic scar tissue generation by pericyte-derived cells. Therapeutic 
agents blocking the interaction of NgR1 with its ligands (362–366) or targeting Nogo-A 
signaling (353–361) may attenuate the inhibitory role that myelin-associated proteins exert on 
axon growth and promote functional recovery via multiple mechanisms, including reduction 
of pericyte-derived scarring. The work presented in this thesis demonstrates that manipulation 
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of inhibitory cues associated with scar tissue, namely attenuation of type A pericyte-derived 
scarring, has potential to improve axonal regeneration and functional recovery following SCI. 
However, it is insufficient to allow the majority of injured CNS axons to regenerate, 
suggesting that a combinatorial therapy might have a higher chance to improve axon 
regeneration and synaptic integration of CNS injured axons. Although some studies suggest 
that modifying the lesion environment has positive repercusions in supraspinal neurons by 
upregulating the expression of axon outgrowth, cell protection, and neural development 
genes (303–306), it is likely that activating intrinsic neuronal growth programs by exogenous 
manipulation (106, 107) would have a stronger effect on promoting axon regeneration. 
Therefore, a suggested combinatorial therapy would involve activating intrinsic neuronal 
growth programs, attenuation of pericyte-derived scarring and intensive rehabilitation 
training, to increase activity-dependent synapse formation into meaningful targets and 
restoration of function (400–402). 
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